Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 17/20 | 0.40 |
| ▸ | JAK2 | O60674 | 16/20 | 0.40 |
| ▸ | JAK3 | P52333 | 16/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17403293 | 0.92 | JAK1 (0.39) | JAK1JAK2JAK3DGAT1TYK2 | |
| SCHEMBL2384374 | 0.90 | JAK2 (0.43) | JAK1JAK2JAK3DGAT1 | |
| SCHEMBL2384364 | 0.90 | JAK2 (0.43) | JAK1JAK2JAK3DGAT1 | |
| SCHEMBL19646533 | 0.90 | JAK2 (0.43) | JAK1JAK2JAK3DGAT1 | |
| SCHEMBL1371116 | 0.89 | JAK2 (0.50) | JAK1JAK2JAK3DGAT1 | |
| SCHEMBL2385721 | 0.86 | JAK2 (0.43) | JAK1JAK2JAK3DGAT1 | |
| SCHEMBL12449399 | 0.85 | JAK2 (0.53) | JAK1JAK2JAK3DGAT1TYK2 | |
| SCHEMBL1370195 | 0.85 | DGAT1 (0.38) | JAK1JAK2JAK3DGAT1TYK2 | |
| SCHEMBL2387681 | 0.85 | DGAT1 (0.38) | JAK1JAK2JAK3DGAT1TYK2 | |
| SCHEMBL1352358 | 0.85 | DGAT1 (0.43) | JAK1JAK2JAK3DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-9827244-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | HOFFMANN LA ROCHE (CH) | 2017-01-05 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9359351-B2 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-07 | — | — | US | disclosed |
| WO-2016005330-A1 | DIHYDROPYRIDOPYRAZINE-1,8-DIONES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF VIRAL DISEASES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-14 | — | — | WO | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000788-A1 | Cap/endo dual inhibitors and their use in the treatment, amelioration or prevention of a viral disease | MME, CAPRIN1, XPNPEP1 | JAK1 4202/4885JAK2 4715/4885JAK3 4076/4885 |
| US-20160002227-A1 | CAP/ENDO DUAL INHIBITORS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | MME, CAPRIN1, XPNPEP1 | JAK1 4202/4885JAK2 4715/4885JAK3 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.